Please login to the form below

Not currently logged in
Email:
Password:

Revolade

This page shows the latest Revolade news and features for those working in and with pharma, biotech and healthcare.

Sobi set to spend up to $915m to acquire Dova Pharmaceuticals

Sobi set to spend up to $915m to acquire Dova Pharmaceuticals

The drug is in the same class as Novartis’ big earner Promacta/Revolade (eltrombopag) which is used to treat low platelet levels caused by hepatitis C virus infection, as well as ... The US biotech is continuing to target Revolade’s territory, and if

Latest news

  • CHMP backs Bayer’s tumour-agnostic drug Vitrakvi CHMP backs Bayer’s tumour-agnostic drug Vitrakvi

    look at two other recent rejections – Novartis’ Revolade (eltrombopag) for severe aplastic anaemia and PTC Therapeutics’ Duchenne muscular dystrophy drug Translarna (ataluren).

  • FDA clears Dova drug for liver-related low blood platelets FDA clears Dova drug for liver-related low blood platelets

    Drug is in the same class as Novartis’ Promacta/Revolade. Dova Pharmaceuticals has won its first product approval, getting a green light from the FDA for Doptelet as a treatment for ... Doptelet is in the same class as Novartis’ Promacta/Revolade

  • Novartis’ Promacta receives US breakthrough therapy designation Novartis’ Promacta receives US breakthrough therapy designation

    Known as Revolade in most countries outside the US, Promacta gained its breakthrough therapy designation following positive data, which 52% of treatment-naïve severe aplastic anaemia (SAA) patients achieved complete response ... Regulatory filings for a

  • CHMP backs orphan drugs Uptravi and Coagadex CHMP backs orphan drugs Uptravi and Coagadex

    new indications for Celgene's multiple myeloma therapy Revlimid (lenalidomide) and Novartis' Revolade (eltrombopag) for idiopathic thrombocytopenic purpura (ITP). ... Revlimid has been backed for the treatment of adult patients with relapsed or

  • Novartis bags EU approvals for three ex-GSK drugs Novartis bags EU approvals for three ex-GSK drugs

    Revolade, Tafinlar and Mekinist all receive regulatory approval. Novartis has been granted EU approvals to three drugs acquired as part of its asset swap deal with GlaxoSmithKline, which closed earlier this ... year. The Swiss company announced this

More from news
Approximately 7 fully matching, plus 11 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics